Novo Nordisk A/S (NYSE:NVO) Shares Sold by Keybank National Association OH

Keybank National Association OH decreased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 59,775 shares of the company's stock after selling 6,722 shares during the period. Keybank National Association OH's holdings in Novo Nordisk A/S were worth $4,151,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Bank of America Corp DE lifted its stake in shares of Novo Nordisk A/S by 8.1% during the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after buying an additional 1,165,955 shares during the period. GQG Partners LLC lifted its stake in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the period. Folketrygdfondet lifted its stake in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock valued at $765,917,000 after buying an additional 40,313 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock valued at $715,084,000 after buying an additional 123,681 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NVO shares. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Down 1.1%

NYSE NVO traded down $0.77 during trading hours on Friday, hitting $69.05. The company had a trading volume of 4,047,911 shares, compared to its average volume of 7,260,792. The firm's 50 day moving average is $69.96 and its 200 day moving average is $75.71. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $143.69. The company has a market capitalization of $308.31 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.